GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.

Inclusion Criteria: * Voluntarily participate in and sign informed consent in person. * Age 18-65, male or non-pregnant female. * Pathological diagnosis of nasopharyngeal non-keratonic carcinoma (differentiated or undifferentiated, i.e., WHO type II or III). * First treatment patients who did not receive antitumor therapy had no history of other malignant tumors; * Stage IVa: TanyN3M0/T4N0-2M0 (8th AJCC/UICC stage) * ECOG score 0-1, no serious dysfunction of heart, lung, liver, kidney and other vital organs. * Hemoglobin (HGB) ≥90 g/L, white blood cells (WBC) ≥4.0×109 /L, platelets (PLT) ≥100×109 /L. * Liver function: ALT and AST\< 2.5 times the upper limit of normal (ULN), total bilirubin \<2.0×ULN. * Renal function: serum creatinine \<1.5×ULN. Exclusion Criteria: * Patients with recurrent and distant metastasis of nasopharyngeal carcinoma. * The pathology was keratinized squamous cell carcinoma (WHO type I). * Received systemic or local glucocorticoid therapy within 4 weeks prior to enrollment. * Participants who had participated in other drug clinical trials within 3 months before treatment. * Patients with a known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation; * Patients with idiopathic pulmonary fibrosis, drug-induced pneumonia, institutional pneumonia (i.e., bronchiolitis obliterans), radiation pneumonia with clinical symptoms or requiring steroid treatment, active pneumonia, or other moderate to severe lung disease…